Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings

Hdl Handle:
http://hdl.handle.net/10144/220338
Title:
Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings
Authors:
Lee, Janice Soo Fern; Calmy, Alexandra; Andrieux-Meyer, Isabelle; Ford, Nathan
Journal:
HIV/AIDS - Research and Palliative Care
Abstract:
Integrase inhibitors represent an important new class of antiretroviral drugs. Elvitegravir, the second available integrase inhibitor to be submitted for regulatory approval appears to be a promising once-daily agent when combined with other antiretroviral drugs. Elvitegravir has demonstrated good efficacy and safety, with minimal side effects and no specific requirements in terms of laboratory monitoring. In addition, elvitegravir is available as a fixed-dose combination. However, the drug requires boosting and this leads to a number of drug-drug interactions and necessary dose adjustment when dosing with certain drugs, including dose reduction in the presence of atazanavir, lopinavir, rifabutin, and ketoconazole, and dose increase for ethinyl estradiol when co-administered with boosted elvitegravir. The main advantage of elvitegravir lies in its potential to be administered as a once-daily, single pill. Limitations include dose adjustment requirements, a relatively low genetic barrier to resistance, high price, and lack of data for use in children. Clinical trials addressing specific challenges encountered in resources-limited settings should be encouraged.
Affiliation:
1Médecins Sans Frontières; HIV/AIDS Unit, Infectious Disease Service, Geneva University Hospital, Geneva, Switzerland; Centre for Infectious Disease Epidemiology and Research, University of Cape Town, South Africa
Publisher:
DovePress
Issue Date:
11-Jan-2012
URI:
http://hdl.handle.net/10144/220338
DOI:
10.2147/HIV.S20993
PubMed ID:
22347806
Additional Links:
http://www.dovepress.com/review-of-the-safety-efficacy-and-pharmacokinetics-of-elvitegravir-wit-peer-reviewed-article-HIV
Type:
Article
Language:
en
ISSN:
1179-1373
Appears in Collections:
HIV/AIDS

Full metadata record

DC FieldValue Language
dc.contributor.authorLee, Janice Soo Fernen
dc.contributor.authorCalmy, Alexandraen
dc.contributor.authorAndrieux-Meyer, Isabelleen
dc.contributor.authorFord, Nathanen
dc.date.accessioned2012-04-24T17:45:05Z-
dc.date.available2012-04-24T17:45:05Z-
dc.date.issued2012-01-11-
dc.identifier.citationHIV AIDS Res Palliat Care 2012; 12(4):5-15en
dc.identifier.issn1179-1373-
dc.identifier.pmid22347806-
dc.identifier.doi10.2147/HIV.S20993-
dc.identifier.urihttp://hdl.handle.net/10144/220338-
dc.description.abstractIntegrase inhibitors represent an important new class of antiretroviral drugs. Elvitegravir, the second available integrase inhibitor to be submitted for regulatory approval appears to be a promising once-daily agent when combined with other antiretroviral drugs. Elvitegravir has demonstrated good efficacy and safety, with minimal side effects and no specific requirements in terms of laboratory monitoring. In addition, elvitegravir is available as a fixed-dose combination. However, the drug requires boosting and this leads to a number of drug-drug interactions and necessary dose adjustment when dosing with certain drugs, including dose reduction in the presence of atazanavir, lopinavir, rifabutin, and ketoconazole, and dose increase for ethinyl estradiol when co-administered with boosted elvitegravir. The main advantage of elvitegravir lies in its potential to be administered as a once-daily, single pill. Limitations include dose adjustment requirements, a relatively low genetic barrier to resistance, high price, and lack of data for use in children. Clinical trials addressing specific challenges encountered in resources-limited settings should be encouraged.en
dc.language.isoenen
dc.publisherDovePressen
dc.relation.urlhttp://www.dovepress.com/review-of-the-safety-efficacy-and-pharmacokinetics-of-elvitegravir-wit-peer-reviewed-article-HIVen
dc.rightsArchived with thanks to HIV/AIDS (Auckland, N.Z.)en
dc.subject.meshAcquired Immunodeficiency Syndromeen
dc.subject.meshAntiviral Agentsen
dc.titleReview of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settingsen
dc.typeArticleen
dc.contributor.department1Médecins Sans Frontières; HIV/AIDS Unit, Infectious Disease Service, Geneva University Hospital, Geneva, Switzerland; Centre for Infectious Disease Epidemiology and Research, University of Cape Town, South Africaen
dc.identifier.journalHIV/AIDS - Research and Palliative Careen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.